Remove DNA Remove Marketing Remove Protein Remove Recombinant DNA Technology
article thumbnail

Exploring the Miracle Antibody Drug Conjugate Technologies

Roots Analysis

Conventional conjugation technologies used for the development of ADCs exploited the superficial lysine residues that were inherent to the native antibody structure, or the inter-chain cysteine residues, for drug-linker attachment. This trend is expected to continue in the foreseeable future.

article thumbnail

Beyond the Pill: The Rise of Biologics and the Evolution of Pharmaceutical Therapies

Cloudbyz

Understanding Biologics: Biologics are a class of therapeutic agents derived from living organisms, such as cells, tissues, or proteins. Unlike traditional small molecule drugs, which are chemically synthesized, biologics are produced through complex biotechnological processes, often involving recombinant DNA technology.

Gene 72
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading innovators in gene splicing using nucleases for the pharmaceutical industry

Pharmaceutical Technology

110 innovations will shape the pharmaceutical industry According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

article thumbnail

Sanofi/GSK restart COVID-19 vaccine trials after tweaking formulation

pharmaphorum

The vaccine is based around an adjuvanted recombinant protein, which will be tested in a new phase 2 study to assess the response including in older adults. But instead rivals such as BioNTech/Pfizer, AstraZeneca and Moderna have made it to market first with their vaccines.